ArticleNanomaterials (Basel, Switzerland)2021
Modulation of the Magnetic Hyperthermia Response Using Different Superparamagnetic Iron Oxide Nanoparticle Morphologies.
Article in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Hybrid Magneto-Plasmonic Nanostructures for Enhanced Dual-Mode Hyperthermia.Nanomaterials (Basel, Switzerland) · 2026Article
- Facile synthesis of FeS-FeNanoscale advances · 2026Article
- Machine Learning on Systematically Curated Data Reveals Key Determinants of Magnetic Hyperthermia Performance.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Insights into Growing Silica Around Monocrystalline Magnetite Nanorods Leading to Colloids with Improved Magnetic Properties-Obstacles and Solutions.Nanomaterials (Basel, Switzerland) · 2026Article
- Magnetic Field-Driven Strategies for Biofilm Disruption: From Iron Oxide Nanoparticles to Adaptive Swarms of Magnetic Microrobots.ACS nano · 2026Review
- Advancements in Superparamagnetic Iron Oxide Nanoparticles for Magnetic Hyperthermia as a Promising Strategy to Combat Antibacterial Resistance.International journal of nanomedicine · 2026Review
- Preparation of biotemplated FeRSC advances · 2025Article
- Engineered PAM-SPION Nanoclusters for Enhanced Cancer Therapy: Integrating Magnetic Targeting with pH-Responsive Drug Release.Molecules (Basel, Switzerland) · 2025Article
- Advanced microfluidic systems with temperature modulation for biological applications.Biomicrofluidics · 2025Article
- Recent advancements and clinical aspects of engineered iron oxide nanoplatforms for magnetic hyperthermia-induced cancer therapy.Materials today. Bio · 2024Review
- Pharmaceutical Quality by Design Approach to Develop High-Performance Nanoparticles for Magnetic Hyperthermia.ACS nano · 2024Article
- Iron Oxide Nanoparticles: Selectively Targeting Melanoma Cells In Vitro by Inducing DNA Damage via H2AX Phosphorylation and Hindering Proliferation through ERK Dephosphorylation.Pharmaceutics · 2024Article
- Optimization of Magnetic Cobalt Ferrite Nanoparticles for Magnetic Heating Applications in Biomedical Technology.Nanomaterials (Basel, Switzerland) · 2023Article
- Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update.Journal of nanobiotechnology · 2022Review
- Progress, Opportunities, and Challenges of Magneto-Plasmonic Nanoparticles under Remote Magnetic and Light Stimulation for Brain-Tissue and Cellular Regeneration.Nanomaterials (Basel, Switzerland) · 2022Review
- Assisted Synthesis of Coated Iron Oxide Nanoparticles for Magnetic Hyperthermia.Nanomaterials (Basel, Switzerland) · 2022Article
- Novel Methacrylate-Based Multilayer Nanofilms with Incorporated FePt-Based Nanoparticles and the Anticancer Drug 5-Fluorouracil for Skin Cancer Treatment.Pharmaceutics · 2022Article
- Synthesis, Development and Characterization of Magnetic Nanomaterials.Nanomaterials (Basel, Switzerland) · 2022Article
- Numerical Simulation of Temperature Variations during the Application of Safety Protocols in Magnetic Particle Hyperthermia.Nanomaterials (Basel, Switzerland) · 2022Article
- Ferrimagnetic Large Single Domain Iron Oxide Nanoparticles for Hyperthermia Applications.Nanomaterials (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The use of magnetic nanoparticles in hyperthermia, that is, heating induced by alternating magnetic fields, is gaining interest as a non-invasive, free of side effects technique that can be considered as a co-adjuvant of other cancer treatments. Having sufficient control on the field characteristics, within admissible limits, the focus is presently on the magnetic material. In the present contribution, no attempt has been made of using other composition than superparamagnetic iron oxide nanoparticles (SPION), or of applying surface functionalization, which opens a wider range of choices. We have used a hydrothermal synthesis route that allows preparing SPION nanoparticles in the 40 nm size range, with spherical, cuboidal or rod-like shapes, by minor changes in the synthesis steps. The three kinds of particles (an attempt to produce star-shaped colloids yielded hematite) were demonstrated to have the magnetite (or maghemite) crystallinity. Magnetization cycles showed virtually no hysteresis and demonstrated the superparamagnetic nature of the particles, cuboidal ones displaying saturation magnetization comparable to bulk magnetite, followed by rods and spheres. The three types were used as hyperthermia agents using magnetic fields of 20 kA/m amplitude and frequency in the range 136-205 kHz. All samples demonstrated to be able to raise the solution temperature from room values to 45 °C in a mere 60 s. Not all of them performed the same way, though. Cuboidal magnetic nanoparticles (MNPs) displayed the maximum heating power (SAR or specific absorption rate), ranging in fact among the highest reported with these geometries and raw magnetite composition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.